Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Healios KK Ord Shs HLOSF

Healthcare Biotechnology
Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which involves research, development and manufacture of regenerative medicine products (iPSC regenerative medicines) utilizing technologies related to induced pluripotent stem cells (iPS cells, iPSCs). The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.


PINL:HLOSF - Post by User

Healios KK Ord Shs
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Post by Linda9on Apr 12, 2010 8:19pm
475 Views
Post# 16983785

Tom H. A. Healy,

Tom H. A. Healy,He is Senior VP, COO of Halo Resources, In Calgary
My husband called him today after close,,,, There is absolutely nothing wrong with HLO operation and progress,,, only positive news on the way however, nobody knows results at this moment... Also He says Sherridon VMS is very advance project for HLO and HBM... Production decision will be made in the near future,.... (in months )...
It was asked delisting concern,,,,, Tom says ..... NO WAY!!!!!!


My buy orders were filled today,, Hate bought only 150000 shares @ 0.05/0.045/ 0.04,,, (50000/order)
Anyway.... We were lucky to get fulfilled @ 0.04!!  average down folks,,,, Let GOLD Copper Zinc Sliver Crack down the roof .... slightly drop into our Accounts!!!

LOL!!!

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities